ProQR Therapeutics (NASDAQ: PRQR) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for ProQR Therapeutics and Acorda Therapeutics, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProQR Therapeutics 0 1 3 0 2.75
Acorda Therapeutics 2 9 2 0 2.00

ProQR Therapeutics presently has a consensus price target of $24.00, indicating a potential upside of 627.27%. Acorda Therapeutics has a consensus price target of $20.58, indicating a potential downside of 19.60%. Given ProQR Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe ProQR Therapeutics is more favorable than Acorda Therapeutics.

Volatility and Risk

ProQR Therapeutics has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500.


This table compares ProQR Therapeutics and Acorda Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ProQR Therapeutics N/A -97.68% -75.50%
Acorda Therapeutics -17.86% -14.76% -7.55%

Institutional and Insider Ownership

31.6% of ProQR Therapeutics shares are held by institutional investors. 7.9% of Acorda Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares ProQR Therapeutics and Acorda Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ProQR Therapeutics N/A N/A -$43.27 million ($2.05) -1.61
Acorda Therapeutics $519.60 million 2.30 -$34.61 million ($1.21) -21.16

Acorda Therapeutics has higher revenue and earnings than ProQR Therapeutics. Acorda Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.


Acorda Therapeutics beats ProQR Therapeutics on 7 of the 13 factors compared between the two stocks.

About ProQR Therapeutics

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide, for the treatment of Leber’s congenital amaurosis (LCA), and QR-313 for the treatment of dystrophic epidermolysis bullosa (DEB).

About Acorda Therapeutics

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and MS. The Company’s product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with's FREE daily email newsletter.